Everand Logo

Welcome to Everand!

  • Discover this podcast and so much more

    Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

    Episode 5: IDH Inhibitors in AML: not so AGILE

    Episode 5: IDH Inhibitors in AML: not so AGILE

    FromWolverHeme Happy Hour

    Start listeningView podcast show

    Episode 5: IDH Inhibitors in AML: not so AGILE

    FromWolverHeme Happy Hour

    ratings:
    Length:
    85 minutes
    Released:
    Jun 3, 2022
    Format:
    Podcast episode

    Description

    In this episode, Bernie Marini and Anthony Perissinotti chat with special guest Charles Foucar, MD, a hematology specialist and expert in the field. We discuss the controversial FDA approval of ivosidenib in combination with azacitidine in newly diagnosed IDH1+ AML, based on the results of the AGILE study: https://www.nejm.org/doi/full/10.1056/NEJMoa2117344
    Released:
    Jun 3, 2022
    Format:
    Podcast episode

    Titles in the series (25)

    Welcome to WolverHeme Happy Hour! This is a podcast dedicated to all things hematology! We discuss new data, debate controversial therapies, and talk about new and exciting research. While we nerd out about data, we'll have a few drinks! Disclaimer: The views and opinions expressed on this podcast are solely those of the podcasters and guests and do not reflect the views or opinions of our employers or other affiliations.